Evidence map›Paper›PMID 33634129›Full record

ReviewFrontiers in cell and developmental biology2021

Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine.

Peter W Halcrow, Jonathan D Geiger, Xuesong Chen

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Chemoresistance: The hidden barrier in cancer treatment.Cancer pathogenesis and therapy · 2026
    Review
  9. Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026
    Review
  10. Article
  11. Autophagy-Related Proteins Influence Mouse Epididymal Sperm Motility.International journal of molecular sciences · 2025
    Article
  12. Article
  13. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Basic and clinical neuroscience · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Peter W HalcrowDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, United States.
Jonathan D GeigerDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, United States.
Xuesong ChenDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, United States.
University of North Dakota · US

Funding

Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GUDA, CHITTIBABU · 2016 to 2025
$42.8M
The Role of Adenosine in Ketogenic Diet TherapyR01NS065957 · NINDS · TRINITY COLLEGE · PI BOISON, DETLEV, GEIGER, JONATHAN DAVID · 2010 to 2021
$3.9M
Effects of opiates on neurons and their impact on HIV neuropathologyR01DA032444 · NIDA · DREXEL UNIVERSITY · PI MEUCCI, OLIMPIA · 2012 to 2023
$3.8M
Tat endolysosome escape and HANDR01MH119000 · NIMH · UNIVERSITY OF NORTH DAKOTA · PI CHEN, XUESONG, GEIGER, JONATHAN DAVID · 2019 to 2023
$2.6M
The role of novel endolysosome-dependent calcium regulatory mechanisms in HIV-1 TR01MH100972 · NIMH · UNIVERSITY OF NORTH DAKOTA · PI CHEN, XUESONG, GEIGER, JONATHAN DAVID · 2014 to 2018
$1.6M
Role of novel endolysosome-dependent calcium regulatory mechanisms in HANDR01MH105329 · NIMH · UNIVERSITY OF NORTH DAKOTA · PI CHEN, XUESONG, GEIGER, JONATHAN DAVID · 2015 to 2019
$1.5M
NIDA NIH HHS R01 DA032444NIGMS NIH HHS U54 GM115458NIMH NIH HHS R01 MH100972NIMH NIH HHS R01 MH105329NIMH NIH HHS R01 MH119000NINDS NIH HHS R01 NS065957
6 · The paper itself

Abstract

Resistance to the anti-cancer effects of chemotherapeutic agents (chemoresistance) is a major issue for people living with cancer and their providers. A diverse set of cellular and inter-organellar signaling changes have been implicated in chemoresistance, but it is still unclear what processes lead to chemoresistance and effective strategies to overcome chemoresistance are lacking. The anti-malaria drugs, chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) are being used for the treatment of various cancers and CQ and HCQ are used in combination with chemotherapeutic drugs to enhance their anti-cancer effects. The widely accepted anti-cancer effect of CQ and HCQ is their ability to inhibit autophagic flux. As diprotic weak bases, CQ and HCQ preferentially accumulate in acidic organelles and neutralize their luminal pH. In addition, CQ and HCQ acidify the cytosolic and extracellular environments; processes implicated in tumorigenesis and cancer. Thus, the anti-cancer effects of CQ and HCQ extend beyond autophagy inhibition. The present review summarizes effects of CQ, HCQ and proton pump inhibitors on pH of various cellular compartments and discuss potential mechanisms underlying their pH-dependent anti-cancer effects. The mechanisms considered here include their ability to de-acidify lysosomes and inhibit autophagosome lysosome fusion, to de-acidify Golgi apparatus and secretory vesicles thus affecting secretion, and to acidify cytoplasm thus disturbing aerobic metabolism. Further, we review the ability of these agents to prevent chemotherapeutic drugs from accumulating in acidic organelles and altering their cytosolic concentrations.

Indexed as

chemoresistancechloroquinecytosolic pHendolysosome pHGolgi pHhydroxychloroquine

Identifiers

PMID33634129
PMCPMC7900406
OpenAlexW3126183343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.